Skip to main content
Breast Cancer Research : BCR logoLink to Breast Cancer Research : BCR
. 2008 Oct 21;10(5):406. doi: 10.1186/bcr2153

Correction: BCoR-L1 variation and breast cancer

Felicity Lose 1,2, Jeremy Arnold 1, David B Young 1, Carolyn J Brown 3, Graham J Mann 4, Gulietta M Pupo 4; The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Kum Kum Khanna 1, Georgia Chenevix-Trench 1, Amanda B Spurdle 1,
PMCID: PMC2614519

Following the publication of our article [1] we noticed that, due to a production error, the figure legends and images were incorrectly matched. All legends were correctly placed, and cited in the text, but were associated with the wrong image.

The figures should therefore appear in the order shown in this correction.

Figure 1.

Figure 1

BcoR-L1 expression in cancer and normal cell lines. (a) BCoR-L1 expression in cancer and normal cell lines. (b) Mean and standard deviation of BCoR-L1 expression in cancer and normal cell lines. Normal cell lines: ovarian – OSE 64/96, HOSE 17.1; breast – SVCT, Bre80hTERT; prostate – RWPE1. BCoR-L1, BCL6 corepressor-like 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 2.

Figure 2

BCoR-L1 haplotype sharing family pedigree detailing carriers of the c.516T>C and c.3608-156C>T variants. Inline graphic = breast cancer-positive; c.516T>C and c.3608-156C>T-positive. Inline graphic = breast cancer-negative; c.516T>C and c.3608-156C>T-positive. Inline graphic = breast cancer-negative; c.516T>C and c.3608-156C>T-negative. ○ = female, □ = male; subjects marked by small shapes were not available for genotyping. BCoR-L1, BCL6 corepressor-like 1.

Figure 3.

Figure 3

BcoR-L1 expression in lymphoblastoid cell lines (LCLs) from breast cancer families. (a) BCoR-L1 expression in LCLs from breast cancer families (normalised to GAPDH). (b) BCoR-L1 expression in LCLs from breast cancer families (normalised to DIDO-1). (c) Mean and standard deviation of BCoR-L1 expression in samples, grouped according to type of family cancer or BCoR-L1 genotype (normalised to GAPDH). (d) Mean and standard deviation of BCoR-L1 expression in samples, grouped according to type of family cancer or BCoR-L1 genotype (normalised to DIDO-1). *Subject also carries a BRCA2 mutation. #Subjects from the same BCoR-L1 haplotype sharing family. BCoR-L1, BCL6 corepressor-like 1; DIDO-1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 4.

Figure 4

Variation in control gene expression. (a) Variation in control gene expression in lymphoblastoid cell lines. (b) Variation in control gene expression in cell lines. DIDO-1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; UBC, ubiquitin C.

References

  1. Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. Khanna KK, Chenevix-Trench G, Spurdle AB. BcoR-L1 variation and breast cancer. Breast Cancer Res. 2007;9:R54. doi: 10.1186/bcr1759. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Breast Cancer Research : BCR are provided here courtesy of BMC

RESOURCES